SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
More2026/05/09
BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months
BEIJING, April 30, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it filed
2026/04/30
Yogyakarta, April 21, 2026 - SINOVAC and Indonesia's Universitas Gadjah Mada, signed a memorandum of understanding in Yogyakarta on April 21, 2026 to deepen R&D cooperation.
2026/04/21
BEIJING, March 27, 2026 — Sinovac Holding Group (“SINOVAC”) and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 20
2026/03/30
SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.
SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.